Human Papillomavirus (HPV) risk and challenges

HPV research is a major driver in changing clinical practice.

Published test results showed that commonly used clinical disinfectants, including those used as sterilants in medical and dental healthcare facilities, have no effect on HPV16 and HPV18.

Research reveals that virtually all cervical cancers (more than 99%) are caused by high-risk Human Papillomaviruses (HPV16 and HPV18 ). HPV is a highly resistant virus; more so than other non-enveloped viruses previously tested.1,3 Published test results showed that commonly used clinical disinfectants, including those used as sterilants in medical and dental healthcare facilities, have no effect on HPV16 and HPV18. Results suggest that healthcare facilities using endocavity ultrasound probes need to strongly consider disinfection methods that are effective against native HPV - adopting new technologies such as UV-C HLD.2

 
Graphs.PNG

Hypernova Chronos is leading the way in High Level Disinfection (HLD) as the only system proven to kill native human papillomavirus (HPV) both in vitro and in clinical use.1,2

Tables.PNG

References:

1. Meyers J, Ryndock E, Conway MJ, Meyers C, Robison R. Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants. J Antimicrob Chemother. 2014;69(6):1546-50.

2. Meyers C, Milici J, Robison R (2017) UVC radiation as an effective disinfectant method to inactivate human papillomaviruses. PLoS ONE 12 (10): e0187377.

3. Maxime Pichon, Karine LebailCarval, Geneviève Billaud, Bruno Lina, Pascal Gaucherand and Yahia Mekki (2019) Decontamination of Intravaginal Probes Infected by Human Papillomavirus (HPV) Using UV-C Decontamination System. J. Clin. Med, 8, 1776; doi:10.3390/jcm8111776.

 
Clinical ResourcesGermitec